Guidelines for the use of cannabinoid compounds in chronic pain.

2005 Autumn;10 Suppl A:44A-6A.

Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D.

Author information

Abstract

OBJECTIVE:

To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain.

METHODS:

Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion.

RESULTS:

There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment ofchronic pain.

CONCLUSIONS:

A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limitee/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.